scholarly journals Perinatal viral hepatitis C and performance capabilities for its therapy

2014 ◽  
Vol 19 (3) ◽  
pp. 4-8
Author(s):  
L. G Goryacheva ◽  
N. V Rogozina ◽  
V. A Greshnyakova ◽  
V. V Ivanova
Keyword(s):  
Hepatitis C ◽  
Clinical Symptoms ◽  
Antiviral Drug ◽  
Sustained Viral Response ◽  
Hcv Infection ◽  
Control Group ◽  
Viral Hepatitis C ◽  
Significant Difference ◽  
And Performance ◽  
Biochemical Indices

The aim of the study: to establish the rate of the vertical transmission of HCV infection and justify the usefulness of the drug a-IFN2b (Viferon®) in children with perinatal infection with hepatitis C virus (HCV) at the early stages of the disease. There were examined 465 children aged 2.5 months to 3 years old (at the time of the enrollment in the study), born to mothers with HCV infection and the frequency of transmission from mother to child was established to be is 7.1% (33 cases). In 54.5% the genotype 1b was recorded, in 3% - 1a, and in 6.0 % - 2 genotype. Viferon® drug in doses of 3х10 6IU/m 2 was introduced to 17 infants aged from 3 to 12 months (duration of the course: 6 months in cases with 3, 2 genotype and 12 months - in patients with genotype 1). The efficacy of therapy was 58.8 % (RNA HCV (-) 10 cases. In prescription the drug to children under 6 months the efficacy was 62.5%, under 6-12 months - 44.4%. In the control group (16patients) spontaneous viral clearance was established to be in 18.7% of cases. The medication did not cause adverse effects and was well tolerated by children. In none out of the 17 children treated with the drug Viferon®, we have not reported adverse events (clinical symptoms, abnormalities in the hemogram and biochemical indices). The obtained data confirm the expediency of the early use of antiviral drug Viferon® in the treatment of children with perinatal HCV. Nо significant difference in the efficacy of therapy in different genotypes of the virus was identified. Virtually in all children (9 out of 10 children) responded to Viferon® therapy, there was noted Sustained Viral Response

Hepatitis C Virus Infection and B-Cell Non-Hodgkin’s Lymphoma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4668-4668
Author(s):  
Janet G. Grudeva
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Hcv Infection ◽  
Control Group ◽  
Cell Infection ◽  
Serum Samples ◽  
Pathogenetic Role ◽  
Significant Difference

Backgroud: An increasing number of bacterial and viral infections have been linked with specific subtypes of lymphoma. Preliminary evidence suggests that hepatitis C virus (HCV) might play a pathogenetic role in autoimmune-related, non-malignant B-cell lymphoproliferation, as well as a subset of B-cell non-Hodgkin, s lymphomas (B-NHL), often with extranodal localization. Design and methods: The study was conducted in the Department of Hematology and consisted 149 (86 male, 63 female) untreated patients with a new diagnosis of B-NHL for 5-years period (2000–2004). HCV infection was investigated by testing for HCV antibodies in serum samples. The controls were 587 patients (without intravenous drug users) in other departments of the same hospital. Results: HCV infection was documented in 13 cases (8,4%) with NHL. The infected patients were not clinically relevant cryoglobulinemic activity, increased rate of autoimmune disorders and extranodal localizations prevalence. There was statistically significant difference between the NHL and control group (p<0,01) and no statistically significant difference between man/women carriers (p>0,05) into the NHL group. Overall, the clinical outcome of HCV-positive NHL does not seem to be different from that of NHL patients without HCV infection. However, the evidence of a significant liver injury may predict a worse prognosis in these cases. Conclusions: Our date suggest that HCV infection may be associated with B-NHL. With regard to the mechanism(s) by which HCV might favor B-cell expansion and malignant transformation, most date support an indirect pathogenetic role of the virus as an exogenous trigger. A direct oncogenetic role of HCV by direct cell infection and deregulation has only been hypothesized on the basis of the lymphotropism of the virus.

scholarly journals OPPORTUNITIES AND PROSPECTS FOR INCORPORATING A THIRD DRUG TO THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

2013 ◽  
Vol 18 (5) ◽  
pp. 9-14
Author(s):  
T. V Sologub ◽  
V. V Tsvetkov ◽  
E. G Deeva ◽  
I. I Tokin
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Clinical Symptoms ◽  
Sustained Viral Response ◽  
Control Group ◽  
Genotype 1 ◽  
Viral Response ◽  
Hcv Genotype 1

In order to evaluate the efficiency and safety of using the drug Ingaron in treatment ofpatients with chronic hepatitis C (CHC) an open, randomized, control comparative study has been performed. We examined of 132 CHC patients aged from 18 to 58 years. All patients were selected into 3 groups depending on the type of therapy. The following drugs: Ribavirin, Alfarona, Ingaron were included in regimens of therapy. The course of the disease in examined CHC patients was characterized by mild clinical symptoms, the presence of the expressed cytolytic syndrome more than in half of the patients (50.8%), high levels of «viral load» in 61.6% of patients with the establishment of a direct correlation between high ALT and viremia levels (r=+0,67). The average level of «viral load» in patients infected with no-1 genotype of hepatitis C, at the start of therapy was 1,4 times higher than in those with genotype 1, amounting to 1,8 x 106 and 1,3 x 106 IU/ml, respectively. Patients infected with HCV genotype 1 and receiving therapy with Ingaron for 24 and 12 weeks, achieved sustained viral response in 65,0% and 80,0% of cases whereas patients infected with «no 1» genotype - in 73,9%, and 84,6% of cases, respectively. At the same time, in patients from the control group the sustained viral response was observed only in 56,0% and 60,0% of cases (1 and «no 1» genotypes, respectively). The inclusion of Ingaron into the classical medical regimen was accompanied by a reduction in the incidence of adverse reactions during treatment.

scholarly journals Screening for chronic hepatitis C and chronic hepatitis B infections among pregnant females: a cross-sectional study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rasha Eletreby ◽  
Maged Abd Elraouf ◽  
Ahmed Fouad ◽  
Mona Nasser ◽  
Mostafa Al Bassiouni ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hcv Infection ◽  
Prevalence Rates ◽  
Cross Sectional ◽  
Screening Programs ◽  
Pregnant Females ◽  
Viral Hepatitis C ◽  
Elisa Testing ◽  
Significant Difference

Abstract Background In Egypt, an endemic country for both viral hepatitis C and B infections, infection could be more prevalent in pregnant females. This study aimed to assess the prevalence of chronic HCV and HBV in a cohort of pregnant Egyptian females, highlighting the disease burden for better preventive measures and better disease outcome. In this cross-sectional prospective study, 399 pregnant women attending antenatal clinic in a tertiary care center in Egypt were screened for HCV and HBV infection using ELISA testing. Clinical and biochemical characteristics were compared between positive and negative cases. Results Mean age was 26.78 years. Prevalence rates of HCV-Ab and HBsAg positivity were 7.02% and 7.52%. Isolated HBcAb positivity was found in only 2 patients (0.5%). All cases were negative for HBsAb. No combined HBV/HCV infection was detected. All positive cases for either HBV or HCV infections did not show any signs of hepatic decompensation. ALT was significantly higher among HBV positive versus negative patients (mean ± SD of 14.2 ± 5.77 IU/L versus 11.95 ± 5.21 IU/L, p = 0.02, reference range: 7-56 IU/L), while no significant difference was found between HCV positive and negative cases as regards liver enzymes. Conclusion In Egypt, HBV prevalence in pregnant females seems to be higher than general population. This was not evident for HCV infection; however, it is still higher than pooled prevalence rates worldwide. This higher prevalence for both viral infections warrants strict screening programs to prevent vertical transmission and to provide better maternal and fetal outcome.

scholarly journals Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection

2020 ◽  
Author(s):  
Romulo Celli ◽  
Saad Saffo ◽  
Saleem Kamili ◽  
Nicholas Wiese ◽  
Tonya Hayden ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Tissue ◽  
Sustained Viral Response ◽  
Antiviral Agent ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Direct Acting Antiviral ◽  
Viral Hepatitis C ◽  
Number Of Patients ◽  
Direct Acting

Context.— Treatment of chronic viral hepatitis C (HCV) infection with direct-acting antiviral agents (DAAs) results in cure, or sustained viral response (SVR), in more than 90% of patients. However, there are subsets of patients who have persistent liver inflammation and fibrosis and develop hepatocellular carcinoma (HCC) despite achieving SVR. A possible reason for these phenomena may be the presence of virus particles in liver tissue but not blood, otherwise defined as occult infection. Objective.— To describe liver histologic findings following successful DAA therapy, test HCV RNA by (liver) tissue polymerase chain reaction in treated cases, and identify predictive markers for HCC development in treated cases. Design.— A total of 96 identified patients were divided into 4 groups, each differentiated by the presence or absence of SVR and HCC. Groups were compared for several clinicopathologic variables, including degree of inflammation and fibrosis, and the ‘directionality' of fibrosis in cirrhotic livers using the novel progressive-indeterminate-regressive scoring system. Results.— Overall, we found a significant decrease in inflammation in SVR patients. None of the patients showed regression of their cirrhosis following treatment. No evidence of occult HCV infection was seen in 40 livers tested, including 21 with HCC. The number of patients who developed HCC was similar in the SVR and non-SVR groups, and increased inflammation and fibrosis were associated with HCC development. Conclusions.— Following DAA-SVR there appears to be an overall decrease in inflammation, but the fibrosis tends to persist, at least in the short term (median follow-up of 20.2 months).

scholarly journals SPECIFIC ASPECTS OF CLINICAL COURSE IN CASE OF COMBINATION OF CHRONIC PANCREATITIS AND CONCOMITANT VIRAL HEPATITIS C

2019 ◽  
Vol 72 (4) ◽  
pp. 595-599
Author(s):  
Liliya S. Babinets ◽  
Olena R. Shaihen ◽  
Halyna Ol. Homyn ◽  
Iryna M. Halabitska
Keyword(s):  
Chronic Pancreatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Symptoms ◽  
Clinical Course ◽  
Negative Influence ◽  
Control Group ◽  
Viral Hepatitis C ◽  
Remission Phase

Introduction: In this publication we analyzed the specific aspects of clinical course in case of combination of chronic pancreatitis and concomitant viral hepatitis C. The aim: Discover the clinical course of chronic pancreatitis with concomitant viral hepatitis C . Materials and methods: 57 patients with chronic pancreatitis and concomitant viral hepatitis c were examined. Diagnosis of chronic pancreatitis and viral hepatitis c was verified based on disease history, clinical symptoms and the results of clinical-instrumental tests. Clinical and biochemical investigations in people with chronic pancreatitis were done in exacerbation and unstable remission phases and for people with viral hepatitis C - in stable remission phase. Results: In patients, who have chronic pancreatitis with concomitant hepatitis C, pain, dyspeptic syndromes and defecation disturbances take the major place in clinical course of the disease. These symptoms were more severe than in the control group (possible difference in numbers in the group of patents with isolate viral hepatitis C (p<0,05). Conclusions: According to the studies data-the negative influence of concomitant viral hepatitis C in clinical course of chronic pancreatitis was identified.

scholarly journals Efficacy of antiviral therapy in patients with hemophilia and hepatitis C virus infection

2009 ◽  
Vol 62 (3-4) ◽  
pp. 129-132
Author(s):  
Velimir Kostic ◽  
Marina Djordjevic ◽  
Lidija Popovic ◽  
Emina Kostic ◽  
Jovana Djordjevic ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Antiviral Therapy ◽  
Sustained Viral Response ◽  
Statistical Processing ◽  
Hcv Infection ◽  
The Other ◽  
Genotype 2 ◽  
Significant Difference

Introduction. HCV infection was common cause of morbidity and mortality in patients with hemophilia before 1986. We wanted to investigate the effect of treatment with combination therapy in HCV positive patients with hemophilia. Material and methods. The research included totally 13 persons afflicted with hemophilia and HCV infection out of 21 tested. The patients were submitted to laboratory and clinical tests as well as genotypization, whereby a different hepatitis C virus genetic adherence was observed. Parallel with this subcategory the other one was put into comparison, consisting of 12 patients afflicted with chronic C hepatitis, marked as non-hemophilics. The both subcategories were treated with combination antiviral therapy (peginterferon a-2a and ribavirin) during 48 weeks for genotype 1 and 4, in reference to 24 weeks for genotype 2 and 3. Within the treatment, clinical and laboratory side-effects were noticed, which did not require therapy interruption. A more frequent hemorrhage during the therapy was found within the hemophilics, rather than before initiliazing it. Results. After the statistical processing of the results (Students' t-test), statistically significant difference among these two subcategories was noticed as values for ALT (***p<0.0001) after 24 weeks of therapy, red blood cells (*p<0.05), haemoglobin and haematocrite (***p<0.0001) 24 weeks after therapy completing. By PCR examination of the patients, 6 months after the end of treatment, a sustained viral response (SVR) of the same percentage was registrated within both subcategories, which is even greater than what the other authors have described. Discussion. Main results were without important difference between two subgroups, except for higher number of spontanuous bleeding in group with hemophilia, which was somewhat expected. Most importantly, we didn't find any difference in SVR rates between groups. Conclusion. HCV positive patients with hemophilia could be successfully treated with combination therapy of peginterferon alfa-2a and ribavirin.

The incidence of hepatitis C virus infection among opiate drug users in Mamoura hospital patient in Alexandria, Egypt

2016 ◽  
Vol 33 (S1) ◽  
pp. S295-S296
Author(s):  
S. Darwish ◽  
N. Sadek ◽  
H. Hoda ◽  
M. Bothaina ◽  
I. Farag
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Liver Function ◽  
Drugs Of Abuse ◽  
Hcv Infection ◽  
Screening Tests ◽  
Control Group ◽  
Group I ◽  
Significant Difference

0 0 1 276 1575 recovery 13 3 1848 14.0 96 800x600 Normal 0 false false false EN-US JA X-NONE.IntroductionEgypt is one of the most famous endemic areas for hepatitis C virus. Drug use in Egypt is rising exponentially. Drug use is always considered one of the main risk factors for HCV.ObjectivesTo assess the effect the route of drug use on the incidence of HCV in the Egyptian population.AimTo study the effects of opiates (tramadol and heroin) use and the route of intake on the incidence of HCV infection among addicts treated in Mamoura mental state hospital, Alexandria, Egypt.MethodsThis is a cross-sectional study on drug dependence patients visiting the out patient clinic for addiction in Elmamora Hospital.Subjects were divided into two groups.Group I: Control group.Twenty non-addict volunteers.Group II: Cases groups (comprising 60 subjects)This group will be divided into three sub-groups each contains 20 cases.Group IIa: consuming tramadol.Group IIb: consuming tramadol and heroin by injection.Group IIc: consuming tramadol and heroin by inhalation.All studied groups were subjected to:.1. detailed history taking, urine screening tests for drugs of abuse, liver functions tests and HCV screening.ResultsThe study showed deterioration in liver function tests in the heroin and tramadol use groups compared to the tramadol only use.There was a statistical significant difference in the incidence of HCV infection in the heroin injection group (85%) compared to 35% in the heroin non injector users and only 5% in tramadol users had HCV positive.ConclusionHeroin injection showed the highest risk for both liver function deterioration and HCV infection.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Serum Interleukin-35 Level in Correlation with T Regulatory and T helper-17 Cells Frequency in Chronic Viral Hepatitis C Patients

2020 ◽  
Vol 14 (4) ◽  
pp. 2431-2442
Author(s):  
Safaa S. Abo-Elnour ◽  
Amira E. Abdelhamid ◽  
Sherine E. Bendary ◽  
Ossama A. Ahmed ◽  
Heba I. Aly ◽  
...  
Keyword(s):  
Hepatitis C ◽  
T Regulatory Cells ◽  
Antiviral Agents ◽  
Control Group ◽  
T Helper ◽  
T Helper 17 ◽  
T Helper 17 Cells ◽  
Th 17 ◽  
Viral Hepatitis C ◽  
Significant Difference

Interleukin-35 (IL-35), secreted mainly by T-regulatory cells (T-regs), has been considered to have immunosuppressive actions in many auto-immune diseases and tumors. However, information about its role in chronic hepatitis C (CHC) infection is still limited. We aimed to study the role of IL-35 within CHC infection and to assess its correlation with T-regs and T-helper 17 cells (Th-17). Therefore, we measured serum IL-35 concentrations using ELISA assay in 25 normal controls (NCs) and in 30 CHC patients before receiving direct antiviral agents (DAA) treatment and after 3 months of treatment end. T-regs and Th-17 cells frequencies were assessed via flow-cytometry in control group and patients’ group before treatment. The results showed that serum IL-35 levels revealed a highly significant increase in CHC patients compared to NCs (P <0.001). Moreover, IL-35 levels significantly decreased in patients 3 months after treatment end (P =0.02). Both Th-17 and T-regs were significantly increased in patients more than in NCs and a positive correlation was observed between them. However, T-regs/Th-17 ratio did not show significant difference from the ratio in NCs. IL-35 levels were positively correlated with viral load and T-regs frequency, but not with Th-17 frequency. IL-35 levels did not correlate with liver enzymes or functions. These results suggested that IL-35 enhances the immunosuppressive functions of T-regs, protecting the liver from HCV induced damage and contributes to viral persistence. IL-35 may represent a possible immunotherapeutic strategy for chronic persistent infection if given with DAA, especially in relapsing or non-responding cases.

Metabolic activity of neutrophils and monocytes in the peripheral blood at the viral hepatitis C

2015 ◽  
Vol 21 (31) ◽  
pp. 14-18
Author(s):  
Цховребов ◽  
Alan Tskhovrebov ◽  
Плахтий ◽  
Lyudmila Plakhtiy ◽  
Гатиева ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Metabolic Activity ◽  
Peripheral Blood ◽  
Clinical Symptoms ◽  
Clinical Manifestations ◽  
Control Group ◽  
Healthy Individuals ◽  
Viral Hepatitis C ◽  
Severity Of The Disease

Survey of 67 patients with viral hepatitis C was made. Of these comorbidities were identified in 11 patients. The survey was conducted at the height of clinical manifestations, in the waning of clinical symptoms in early convalescence. The control group consisted of 27 healthy individuals. In patients with hepatitis C dysfunction of neutrophils and monocyteswas revealed. These changescorrelate with the severity of the process. A consequence of the metabolic defect is a decrease in phagocytic activity of neutrophils and monocytes, which allows to offer methods of studying the metabolism of peripheral blood phagocytes as additional criteria to assess the severity of the disease, the prognosis of viral Hepatitis C, its outcomes and complications.

scholarly journals Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study

2021 ◽  
Vol 18 (7) ◽  
pp. 3694
Author(s):  
Irina Paula Doica ◽  
Dan Nicolae Florescu ◽  
Carmen Nicoleta Oancea ◽  
Adina Turcu-Stiolica ◽  
Mihaela-Simona Subtirelu ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Medication Adherence ◽  
Pilot Study ◽  
Multidisciplinary Approach ◽  
Therapy Monitoring ◽  
Antiviral Agents ◽  
Item Score ◽  
Hcv Therapy ◽  
Viral Hepatitis C ◽  
Significant Difference

The COVID-19 pandemic is currently delaying the process of chronic hepatitis C (HCV) eradication, since most of the chronic diseases are neglected. Thus, there is a need for alternative programs for HCV therapy implementation and disease monitoring. Our aim was to provide a multidisciplinary approach, so that HCV-infected patients from distant locations may benefit from HCV antivirals during the COVID-19 outbreak and within the lockdown period in Romania. Previously diagnosed HCV patients willing to participate in this telemedicine pilot study were included. Patient characteristics and medical adherence were assessed and compared to the year preceding the pandemic. We proposed a multidisciplinary approach by using a telemedicine program for HCV therapy monitoring. Patients also received a satisfaction questionnaire after delivering the sustained virologic response (SVR) result. A total of 41 patients agreed to participate in this study. The medication adherence was 100% for patients included in the telemedicine group, with a statistically significant difference from the medication adherence of the patients treated in 2019. The satisfaction item score was 4.92 out of 5 and our results (r = −0.94, p < 0.0001) suggested that older patients embraced the telemedicine program less, but with the same success in terms of SVR (100%) and medication adherence (100%). Our pilot study offers the first example of a telemedicine program in Romania for HCV therapeutic management. During the lockdown period, telemedicine has served as a reliable tool and novel alternative for conventional monitoring of patients treated with direct antiviral agents and should be further considered even following the pandemic.

Sign in / Sign up

Export Citation Format

Share Document